Guillaume Louvel
Guillaume Louvel has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Katarzyna Holub
Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain
2 shared publications - Alexandre Delpla
Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France.
1 shared publication - Amandine Berdelou
Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, 114 rue Edouard Vaillant, 94800 Villejuif, France
1 shared publication - Annalisa Guida
Medical and Translational Oncology Unit, Department of Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy
1 shared publication Antoine Petit
Department of Neurosurgery, University Hospital Jean Minjoz, Besançon, France
1 shared publication- Antonin Levy
Department of Radiation Oncology, Gustave Roussy, Villejuif, France
1 shared publication
Latest Publications
- 15 February 2021
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 152 (2) , 383-393
Poor performance status and brain metastases treatment: who may benefit from the stereotactic radiotherapy?
Background Poor Performance Status (PS) of cancer patients, defined as PS score 2–3, is an impediment for many drug- and irradiation-based treatments, supported by the trials that exclude subjects with PS < 1. Reports on the benefits of stereotactic radiotherapy (SRT) for brain metastases (BMs) in poor PS patients are scarce. We sought to review the characteristics and survival outcomes of this cohort, to assess who may benefit most from SRT. Methods We retrospectively evaluated 73 patients with PS 2 or 3 (63 and 10 cases) treated with SRT for 150 BMs from 2012 to 2018. Patients’ characteristics and post-SRT survival, stratified by concomitant systemic treatment (CST) were assessed using the Kaplan–Meier method (p-value < 0.05). Results Non-small cell lung cancer was the most frequent primary tumor. Extracranial metastases were present in 86.3% of patients. The median overall survival (mOS) after SRT was estimated as 6.0 months (range 0.2–37.7), with 6- and 12-month survival rates of 51.0% and 21.0%, respectively. CST was administrated to 59.7% of patients (immunotherapy, target therapy or chemotherapy). Patients treated with CST presented larger mOS (6.7 vs. 4.4 months for patients treated with SRT alone, p = 0.3), and better 6- and 12-month survival rates (59% and 24% vs. 37% and 18% in patients not treated with CST). Conclusions Survival rate after SRT for BMs in poor performance patients, especially with PS 2, can justify SRT, in particular if an effective systemic treatment is available. Both SRT and CST should be more accessible for these patients in clinical practice.
- 15 February 2021
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 152 (2) , 383-393
Poor performance status and brain metastases treatment: who may benefit from the stereotactic radiotherapy?
Background Poor Performance Status (PS) of cancer patients, defined as PS score 2–3, is an impediment for many drug- and irradiation-based treatments, supported by the trials that exclude subjects with PS < 1. Reports on the benefits of stereotactic radiotherapy (SRT) for brain metastases (BMs) in poor PS patients are scarce. We sought to review the characteristics and survival outcomes of this cohort, to assess who may benefit most from SRT. Methods We retrospectively evaluated 73 patients with PS 2 or 3 (63 and 10 cases) treated with SRT for 150 BMs from 2012 to 2018. Patients’ characteristics and post-SRT survival, stratified by concomitant systemic treatment (CST) were assessed using the Kaplan–Meier method (p-value < 0.05). Results Non-small cell lung cancer was the most frequent primary tumor. Extracranial metastases were present in 86.3% of patients. The median overall survival (mOS) after SRT was estimated as 6.0 months (range 0.2–37.7), with 6- and 12-month survival rates of 51.0% and 21.0%, respectively. CST was administrated to 59.7% of patients (immunotherapy, target therapy or chemotherapy). Patients treated with CST presented larger mOS (6.7 vs. 4.4 months for patients treated with SRT alone, p = 0.3), and better 6- and 12-month survival rates (59% and 24% vs. 37% and 18% in patients not treated with CST). Conclusions Survival rate after SRT for BMs in poor performance patients, especially with PS 2, can justify SRT, in particular if an effective systemic treatment is available. Both SRT and CST should be more accessible for these patients in clinical practice.
- 19 January 2021
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 23 (7) , 1463-1473
Efficacy of salvage stereotactic radiotherapy (SRT) for locally recurrent brain metastases after initial SRT and characteristics of target population
Objectives Due to a steadily growing use of stereotactic radiotherapy (SRT) for treatment of brain metastases (BMs), the in-field failure after an initial stereotaxy is an increasingly frequent problem. Repeat stereotactic radiotherapy (re-SRT) shows encouraging results in terms of local control. However, the evidence on prognostic factors limiting the overall survival (OS) of re-treated patients is scarce. Here, we sought to analyze the patients’ and treatment characteristics influencing the survival outcomes after re-SRT. Methods Data of all patients with local failure of initial SRT treated from 2012 to 2019 were retrospectively reviewed and cases treated with salvage SRT were analyzed. We analyzed the impact of patients’ and treatment characteristics on overall survival after re-SRT by Kaplan–Meier method and Cox regression models. Local and distant brain control, cause of death, and radionecrosis rate were also assessed. Results Forty-seven patients with 55 BMs treated with re-SRT were evaluated. Median OS after re-SRT was 9.2 months and the overall local control was 83.6%. Nine BMs (16.4%) presented local relapse (LR), 12 (21.8%) radionecrosis, while 21 patients (44.7%) developed new BMs. Only absence of extracranial metastases at BMs diagnosis (HR 0.42, CI 95%; 0.18–0.97), extracranial disease progression (HR 2.39, CI 95%; 1.06–5.38) and distant brain failure (HR 3.94, CI 95%; 1.68–9.24) after re-SRT were significantly associated with patients’ survival. Extracranial progression following re-SRT was an independent prognosticator of worse OS. Conclusion Re-SRT after LR presented excellent local control with acceptable RN rate and improved patients’ survival, limited mainly by extracranial and distant brain progression.
- 19 January 2021
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 23 (7) , 1463-1473
Efficacy of salvage stereotactic radiotherapy (SRT) for locally recurrent brain metastases after initial SRT and characteristics of target population
Objectives Due to a steadily growing use of stereotactic radiotherapy (SRT) for treatment of brain metastases (BMs), the in-field failure after an initial stereotaxy is an increasingly frequent problem. Repeat stereotactic radiotherapy (re-SRT) shows encouraging results in terms of local control. However, the evidence on prognostic factors limiting the overall survival (OS) of re-treated patients is scarce. Here, we sought to analyze the patients’ and treatment characteristics influencing the survival outcomes after re-SRT. Methods Data of all patients with local failure of initial SRT treated from 2012 to 2019 were retrospectively reviewed and cases treated with salvage SRT were analyzed. We analyzed the impact of patients’ and treatment characteristics on overall survival after re-SRT by Kaplan–Meier method and Cox regression models. Local and distant brain control, cause of death, and radionecrosis rate were also assessed. Results Forty-seven patients with 55 BMs treated with re-SRT were evaluated. Median OS after re-SRT was 9.2 months and the overall local control was 83.6%. Nine BMs (16.4%) presented local relapse (LR), 12 (21.8%) radionecrosis, while 21 patients (44.7%) developed new BMs. Only absence of extracranial metastases at BMs diagnosis (HR 0.42, CI 95%; 0.18–0.97), extracranial disease progression (HR 2.39, CI 95%; 1.06–5.38) and distant brain failure (HR 3.94, CI 95%; 1.68–9.24) after re-SRT were significantly associated with patients’ survival. Extracranial progression following re-SRT was an independent prognosticator of worse OS. Conclusion Re-SRT after LR presented excellent local control with acceptable RN rate and improved patients’ survival, limited mainly by extracranial and distant brain progression.
- 1 October 2019
- Published by Elsevier in European Journal of Radiology
- Vol. 119, 108650
Thermal-ablation of vertebral metastases prevents adverse events in patients with differentiated thyroid carcinoma
- 1 October 2019
- Published by Elsevier in European Journal of Radiology
- Vol. 119, 108650
Thermal-ablation of vertebral metastases prevents adverse events in patients with differentiated thyroid carcinoma
- 4 January 2018
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 51 (1) , 1701737
Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?
Cases of radiation pneumonitis developed after concomitant checkpoint inhibitors and lung SBRT: a matter of concern?http://ow.ly/k78q30g1qDJ
- 4 January 2018
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 51 (1) , 1701737
Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?
Cases of radiation pneumonitis developed after concomitant checkpoint inhibitors and lung SBRT: a matter of concern?http://ow.ly/k78q30g1qDJ
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 4561
Prognosis of brain metastasis (BM) in metastatic renal cell carcinoma (mRCC): Experience from Gustave Roussy (IGR).
4561 Background: BM occur in 2-16% of patients (pts) with mRCC and are associated with a poor outcome. However, BM appear at different stage of the disease, and various therapies can be proposed. The aim of this study was to find out potential prognostic factors in this heterogeneous group of pts. Methods: Metastatic RCC pts with radiological evidence of BM, followed at IGR from 1997 to 2015 were analyzed. Pts characteristics, treatments and outcome data were collected. Tumor burden (TB) at the time of BM was defined according to RECIST 1.1. OS was calculated from date of BM diagnosis to death for any cause or last follow-up using the Kaplan-Maier method and modelled with the Cox-regression model. Results: 162 pts were included in this retrospective study. Most pts (95%) had clear-cell histology. Half pts (54%) had synchronous metastatic disease. In 36% of cases BM occurred before the start of 1-line therapy, in 37% before the start of 2-line. The most common metastatic sites at the time of BM diagnosis were: lung 79%, lymph nodes 54% and bones 34%. Using International Metastatic Renal Cancer Database Consortium (IMDC) prognostic score, pts were classified as good 24%, intermediate 54% and poor 22% risk when BM was diagnosed. Two third of pts (66%) were diagnosed of a single BM, while 14% had ≥ 3. Neurological symptoms (NS) were present in 61% of cases. Local treatments (LT) were: surgery 28%, stereotaxic radiotherapy (SRT) 30%, whole-brain radiotherapy (WBRT) 24%, while 25% did not receive local treatment. With a median follow up of 44 months (mo), median OS for pts with BM was 12 mo. In multivariate analysis (table), NS, TB, time to BM (TTBM), number of line of therapy, and the use of a local therapy appear significantly correlated with OS. Conclusions: This is the largest series of BM from mRCC. In this series, characteristics of the disease appear to be more important than the type of local treatment of BM in terms of prognosis.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 4561
Prognosis of brain metastasis (BM) in metastatic renal cell carcinoma (mRCC): Experience from Gustave Roussy (IGR).
4561 Background: BM occur in 2-16% of patients (pts) with mRCC and are associated with a poor outcome. However, BM appear at different stage of the disease, and various therapies can be proposed. The aim of this study was to find out potential prognostic factors in this heterogeneous group of pts. Methods: Metastatic RCC pts with radiological evidence of BM, followed at IGR from 1997 to 2015 were analyzed. Pts characteristics, treatments and outcome data were collected. Tumor burden (TB) at the time of BM was defined according to RECIST 1.1. OS was calculated from date of BM diagnosis to death for any cause or last follow-up using the Kaplan-Maier method and modelled with the Cox-regression model. Results: 162 pts were included in this retrospective study. Most pts (95%) had clear-cell histology. Half pts (54%) had synchronous metastatic disease. In 36% of cases BM occurred before the start of 1-line therapy, in 37% before the start of 2-line. The most common metastatic sites at the time of BM diagnosis were: lung 79%, lymph nodes 54% and bones 34%. Using International Metastatic Renal Cancer Database Consortium (IMDC) prognostic score, pts were classified as good 24%, intermediate 54% and poor 22% risk when BM was diagnosed. Two third of pts (66%) were diagnosed of a single BM, while 14% had ≥ 3. Neurological symptoms (NS) were present in 61% of cases. Local treatments (LT) were: surgery 28%, stereotaxic radiotherapy (SRT) 30%, whole-brain radiotherapy (WBRT) 24%, while 25% did not receive local treatment. With a median follow up of 44 months (mo), median OS for pts with BM was 12 mo. In multivariate analysis (table), NS, TB, time to BM (TTBM), number of line of therapy, and the use of a local therapy appear significantly correlated with OS. Conclusions: This is the largest series of BM from mRCC. In this series, characteristics of the disease appear to be more important than the type of local treatment of BM in terms of prognosis.
- 1 January 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 118 (1) , 9-15
Delaying standard combined chemoradiotherapy after surgical resection does not impact survival in newly diagnosed glioblastoma patients
- 1 January 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 118 (1) , 9-15
Delaying standard combined chemoradiotherapy after surgical resection does not impact survival in newly diagnosed glioblastoma patients